Novo Nordisk Highlights Semaglutide Benefits and Pipeline at ADA

Novo Nordisk Unveils Semaglutide Benefits and Pipeline Strategy at ADA

Novo Nordisk presented over 40 abstracts and engaged with analysts at the American Diabetes Association (ADA) conference, impressing BMO Capital Markets with its strategic vision. The company showcased new posthoc analyses of semaglutide (Wegovy/Ozempic), demonstrating benefits in asthma-related adverse outcomes and systolic blood pressure in patients with uncontrolled hypertension and overweight or obesity. Data from the SELECT cardiovascular outcomes trial indicated a reduction in adverse events for semaglutide-treated patients with asthma and obesity. Additionally, analyses from the STEP and OASIS trials showed meaningful improvements in systolic blood pressure and fatty liver index scores. Novo Nordisk also highlighted its extensive cardiometabolic pipeline, including ziltivekimab (Phase 3 ZEUS trial) and CagriSema, with an FDA decision for CagriSema in obesity anticipated by year-end. The oral Wegovy pill launch is exceeding expectations, surpassing 3 million prescriptions.

• Novo Nordisk presented new posthoc analyses at ADA, revealing broader benefits of semaglutide beyond weight loss and diabetes. Data from the SELECT cardiovascular outcomes trial showed that patients with cardiovascular disease, asthma, and obesity/overweight treated with semaglutide experienced significantly fewer adverse events compared to placebo. Further analyses from the STEP and OASIS trials demonstrated meaningful improvements in systolic blood pressure and reductions in fatty liver index scores in patients with overweight or obesity and uncontrolled hypertension.
• The company emphasized its robust and differentiated cardiometabolic disease pipeline, leveraging over 49 million cumulative patient years of experience with semaglutide. Key pipeline assets include ziltivekimab, a once-monthly IL-6 inhibitor currently in the Phase 3 ZEUS trial for atherosclerotic cardiovascular disease with chronic kidney disease, with data expected in the second half of this year. Novo Nordisk is also advancing CagriSema, a combination of semaglutide and cagrilintide, with an FDA decision for obesity anticipated by the end of the year and plans for a new drug application in type 2 diabetes.
• Novo Nordisk reported significant commercial success with the launch of its oral Wegovy pill, which has surpassed 3 million prescriptions, equating to approximately one prescription filled every five seconds. This strong performance provides increased confidence in the company's commercial business, despite competitive pressures in the weight loss market. The oral GLP-1 option received FDA approval in December 2025, marking a pivotal advancement in accessible weight management therapies.

Semaglutide's Expanding Benefits: Asthma, Hypertension, and Liver Health

Semaglutide is being investigated across multiple therapeutic areas beyond obesity, with substantial clinical trial programs underway. The most advanced programs include early-stage Alzheimer's disease, metabolic dysfunction-associated steatohepatitis (MASH), and various cardiovascular and renal complications in type 2 diabetes patients.

• Early-stage Alzheimer's Disease: Two global, multicenter, randomized, double-blind, placebo-controlled phase 3 trials (EVOKE and EVOKE+) are investigating oral semaglutide 14 mg in 9,996 participants with early-stage symptomatic Alzheimer's disease and confirmed amyloid positivity, with primary readouts expected in the second half of 2025

• Metabolic Dysfunction-Associated Steatohepatitis (MASH): Clinical trials demonstrate semaglutide significantly improves MASH resolution and reduces liver steatosis, with subgroup analyses showing greatest benefits in patients receiving higher doses (≥2.0 mg weekly) and longer intervention durations (≥12 months)

• Cardiovascular Outcomes in Type 2 Diabetes: Cardiovascular outcome trials (CVOTs) have established superiority over placebo for the primary composite endpoint of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke in patients with type 2 diabetes and cardiovascular disease

• Renal Complications: Clinical trials are evaluating renal outcomes including estimated glomerular filtration rate (eGFR) and urinary albumin-to-creatinine ratio (UACR), with marked reductions observed particularly in albuminuria outcomes with semaglutide 1 mg

• Metabolic Syndrome with Comorbid Hypothyroidism: Single-center retrospective studies are investigating oral semaglutide 14 mg daily in patients with confirmed hypothyroidism and type 2 diabetes, showing significant improvements in HbA1c, BMI, and lipid profiles over 6-month monitoring periods

Novo Nordisk's Pipeline: CagriSema and Emerging Combination Therapies

Recent clinical trials have demonstrated promising results for several combination therapy approaches in obesity treatment, with particular focus on enhancing the efficacy of established incretin-based therapies. The combination of bimagrumab, an investigational antibody targeting type II activin receptors, with semaglutide has shown remarkable synergistic effects in a phase 2 trial involving 507 adults with obesity. The high-dose combination (bimagrumab 30 mg/kg plus semaglutide 2.4 mg) achieved -17.8 kg weight loss at week 48 compared to -3.3 kg with placebo, substantially exceeding the weight loss observed with either agent alone (-9.3 kg with bimagrumab 30 mg/kg alone and -14.2 kg with semaglutide 2.4 mg alone). Additionally, tirzepatide has been investigated in specialized populations, including a phase II trial combining it with standard fertility-sparing treatment in obese patients with endometrial cancer and atypical hyperplasia, where its role as the most effective GLP-1 receptor agonist for weight control is being leveraged for dual therapeutic benefit.

The development of triple agonist approaches represents a significant advancement in combination therapy strategies, with compounds targeting GLP-1, GIP, and glucagon receptors simultaneously. Retatrutide, the most advanced triple agonist candidate, has demonstrated exceptional efficacy in phase 2 trials, achieving up to 24.2% mean weight loss after 48 weeks in individuals with obesity while improving multiple cardiometabolic parameters including blood pressure, lipids, and achieving an 82% reduction in hepatic steatosis. Other GCGR-based multi-agonists including mazdutide and survodutide have shown substantial efficacy for weight loss while improving liver health in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), with comprehensive phase 3 programs currently ongoing to evaluate their long-term efficacy and cardiovascular outcomes.

Lifestyle intervention combinations have also shown measurable benefits, particularly time-restricted eating (TRE) protocols combined with nutrition and exercise counseling. Clinical trials from 2015 to 2025 demonstrated that TRE with professional guidance can achieve 3-5% body weight reduction and improve glycated hemoglobin by 0.3-0.5%, with TRE-8 (8-hour daily eating duration) and early eating window approaches showing particular promise due to circadian rhythm alignment. Post hoc analyses of major trials like SURMOUNT have also validated that established therapies like tirzepatide maintain their efficacy even in challenging populations using concomitant weight-inducing medications, with weight loss ranging from -13.3% to -21.3% depending on dose despite the presence of medications that typically promote weight gain.

The Evolving Obesity Treatment Landscape: A Novo-Lilly Showdown

The obesity treatment landscape has undergone a fundamental transformation over the past five years, driven predominantly by the emergence and clinical validation of incretin-based therapies. A systematic review of 275 clinical trials registered between October 2019 and October 2024 revealed that incretin pathway modulators dominated the research pipeline at 69.8%, with GLP-1 receptor agonists and dual or triple agonists targeting GLP-1, GIP, and glucagon receptors representing the primary focus. This shift reflects a maturation of the pipeline, with most trials progressing to Phase 2 (40.7%) or Phase 3 (31.3%) stages, while early-stage innovation remained limited at only 3.3%. Drug repurposing was notably common at 22.2%, particularly involving semaglutide and liraglutide, originally developed for type 2 diabetes management.

The clinical efficacy profile of GLP-1 receptor agonists has been comprehensively established through robust meta-analytic evidence. A 2025 meta-analysis encompassing 47 randomized controlled trials with 23,244 patients demonstrated mean weight reductions of -4.57 kg, mean BMI reductions of -2.07 kg/m², and mean waist circumference reductions of -4.55 cm compared with placebo. These effects remained consistent across diabetes status, specific GLP-1 RA formulations, and administration routes, with greatest treatment benefits observed in younger, female patients without diabetes who had higher baseline weight and BMI but lower baseline HbA1c levels. The landscape has expanded beyond monotherapies to include novel dual and triple receptor agonists, with tirzepatide (GLP-1/GIP co-agonist) demonstrating up to 22.5% weight loss in phase 3 obesity trials, and retatrutide (GLP-1/GIP/glucagon triple agonist) achieving 24.4% weight loss at 48 weeks in phase 2 studies.

The translational impact of these therapeutic advances has begun reshaping clinical practice patterns and patient care pathways. Real-world effectiveness studies comparing anti-obesity medications over six months showed phentermine achieving 87.2% of patients reaching ≥5% weight loss, while liraglutide achieved 58.1%, indicating sustained efficacy across diverse treatment populations. Referral patterns for body-contouring procedures between 2022 and 2024 demonstrated an emerging trend toward GLP-1 RA-associated referrals, with semaglutide representing 78.3% of pharmacological therapy cases. The pediatric treatment landscape has also evolved significantly, with liraglutide receiving FDA approval in 2020 for children aged 12-17 years with obesity, while ongoing trials are evaluating semaglutide in pediatric populations, reflecting a comprehensive approach to obesity management across age groups.